Evidence network for deaths_(OS)

1EMILIA, 20121WJOG6110B/ELTOP, 20181HER2CLIMB, 20201DESTINY Breast03, 20221SOPHIA, 20212NALA, 2020 NALA (brain metastases), 20201CLEOPATRA, 20121EGF104900, 20101LUX-Breast 1, 20161AVEREL, 20131SYSUCC-002, 2022placebotrastuzumab plus capecitabinetrastuzumab emtansinelapatinib plus capecitabinechemotherapytrastuzumab plus chemotherapyvinorelbinetrastuzumab plus docetaxelcapecitabinelapatinibtrastuzumab plus vinorelbinepertuzumab plus trastuzumab plus cyclophosphamidetrastuzumabneratinibtucatinib plus trastuzumab plus capecitabinetrastuzumab deruxtecanmargetuximab plus chemotherapyinetetamab plus vinorelbineneratinib plus capecitabinepertuzumab plus trastuzumab plus docetaxellapatinib plus trastuzumabafatinib plus vinorelbinebevacizumab plus trastuzumab plus docetaxelpertuzumab plus trastuzumabtrastuzumab plus endocrine therapydirect evidencenetwork meta-analysis
T vs. C placebotrastuzumab plus capecitabinetrastuzumab emtansinelapatinib plus capecitabinechemotherapytrastuzumab plus chemotherapyvinorelbinetrastuzumab plus docetaxelcapecitabinelapatinibtrastuzumab plus vinorelbinepertuzumab plus trastuzumab plus cyclophosphamidetrastuzumabneratinibtucatinib plus trastuzumab plus capecitabinetrastuzumab deruxtecanmargetuximab plus chemotherapyinetetamab plus vinorelbineneratinib plus capecitabinepertuzumab plus trastuzumab plus docetaxellapatinib plus trastuzumabafatinib plus vinorelbinebevacizumab plus trastuzumab plus docetaxelpertuzumab plus trastuzumabtrastuzumab plus endocrine therapy
placebo---NANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus capecitabineNA---NANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab emtansineNANA---NANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus capecitabineNANANA---NANANANANANANANANANANANANANANANANANANANANA
chemotherapyNANANANA---NANANANANANANANANANANANANANANANANANANANA
trastuzumab plus chemotherapyNANANANANA---NANANANANANANANANANANANANANANANANANANA
vinorelbineNANANANANANA---NANANANANANANANANANANANANANANANANANA
trastuzumab plus docetaxelNANANANANANANA---NANANANANANANANANANANANANANANANANA
capecitabineNANANANANANANANA---NANANANANANANANANANANANANANANANA
lapatinibNANANANANANANANANA---NANANANANANANANANANANANANANANA
trastuzumab plus vinorelbineNANANANANANANANANANA---NANANANANANANANANANANANANANA
pertuzumab plus trastuzumab plus cyclophosphamideNANANANANANANANANANANA---NANANANANANANANANANANANANA
trastuzumabNANANANANANANANANANANANA---NANANANANANANANANANANANA
neratinibNANANANANANANANANANANANANA---NANANANANANANANANANANA
tucatinib plus trastuzumab plus capecitabineNANANANANANANANANANANANANANA---NANANANANANANANANANA
trastuzumab deruxtecanNANANANANANANANANANANANANANANA---NANANANANANANANANA
margetuximab plus chemotherapyNANANANANANANANANANANANANANANANA---NANANANANANANANA
inetetamab plus vinorelbineNANANANANANANANANANANANANANANANANA---NANANANANANANA
neratinib plus capecitabineNANANANANANANANANANANANANANANANANANA---NANANANANANA
pertuzumab plus trastuzumab plus docetaxelNANANANANANANANANANANANANANANANANANANA---NANANANANA
lapatinib plus trastuzumabNANANANANANANANANANANANANANANANANANANANA---NANANANA
afatinib plus vinorelbineNANANANANANANANANANANANANANANANANANANANANA---NANANA
bevacizumab plus trastuzumab plus docetaxelNANANANANANANANANANANANANANANANANANANANANANA---NANA
pertuzumab plus trastuzumabNANANANANANANANANANANANANANANANANANANANANANANA---NA
trastuzumab plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANA---

pathologies: 355,337,146,317 - treatments: 1429 result logic